Curie Capital is a life science-focused venture capital firm established in 2018 and headquartered in Amsterdam, Netherlands. The firm aims to invest in early-stage companies within the biotechnology, pharmaceutical, and medical technology sectors, with particular emphasis on therapeutics, diagnostics, and medical devices. Founded by Mariette van der Velden and Han de Groot, both of whom possess extensive experience in investing and entrepreneurship, Curie Capital combines their complementary skills and networks to support the development of talented teams and innovative science and technology. The firm seeks to foster the growth of its portfolio companies from inception through to potential public exit.
Avidicure is a cancer care company focused on enhancing immune system function through innovative therapies. It is developing a novel antibody modality known as "AVC-Boosters," which are dual agonistic and multifunctional, engineered to deliver targeted and effective monotherapy. This approach aims to provide broad applicability in oncology, addressing various cancer types while prioritizing safety and efficacy. Currently, Avidicure is operating in stealth mode, indicating a focus on research and development before public engagement.
Sirius Medical
Venture Round in 2025
Sirius Medical helps improve healthcare for cancer patients by developing medical devices that aid in surgical treatment. Their objective is to create intuitive and accurate gadgets that allow surgeons and radiologists to provide the finest treatment. Sirius Perception uses audio and visual feedback to provide real-time, directional advice for pinpointing tumors
Citryll
Series B in 2024
Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.
Flindr Therapeutics
Series A in 2024
Flindr Therapeutics, a private biotech company develops next-generation precision oncology treatments.
Sirius Medical
Series B in 2023
Sirius Medical helps improve healthcare for cancer patients by developing medical devices that aid in surgical treatment. Their objective is to create intuitive and accurate gadgets that allow surgeons and radiologists to provide the finest treatment. Sirius Perception uses audio and visual feedback to provide real-time, directional advice for pinpointing tumors
Cleara Biotech
Seed Round in 2022
Cleara Biotech B.V., based in Utrecht, the Netherlands, focuses on developing therapeutics aimed at selectively eliminating senescent and senescent-like cancer cells. The company is particularly engaged in creating FOXO4-based anti-senescence drugs designed to counteract chemotoxicity and address therapy-resistant cancer cells. By targeting these problematic cells, Cleara Biotech seeks to advance cancer treatment and improve patient outcomes.
TargED Biopharmaceuticals
Series A in 2022
TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.
Sirius Medical
Series A in 2021
Sirius Medical helps improve healthcare for cancer patients by developing medical devices that aid in surgical treatment. Their objective is to create intuitive and accurate gadgets that allow surgeons and radiologists to provide the finest treatment. Sirius Perception uses audio and visual feedback to provide real-time, directional advice for pinpointing tumors
TargED Biopharmaceuticals
Seed Round in 2020
TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.
Sirius Medical
Series A in 2020
Sirius Medical helps improve healthcare for cancer patients by developing medical devices that aid in surgical treatment. Their objective is to create intuitive and accurate gadgets that allow surgeons and radiologists to provide the finest treatment. Sirius Perception uses audio and visual feedback to provide real-time, directional advice for pinpointing tumors
Citryll
Series A in 2019
Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.